Oppenheimer Price Target Adjusted To Over +300% Of Current Price

Oppenheimer Price Target Adjusted To Over +300% Of Current Price

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, August 17, 2022

A Salt Lake City-based biotech company found tremendous success on Wednesday after Oppenheimer adjusted its price target to $17.00 from $16.00. While this $1 move isn’t necessarily groundbreaking news, the fact that shares are currently trading around $4.00, traders couldn’t seem to get their hands on shares of Clene Inc. (Nasdaq:CLNN) fast enough.

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Traders were extremely bullish on the new price target as shares of Clene Inc. reached $4.12/share (+13.50%) at the session high. With this amount of upside until the price target, it’ll be interesting to see how this small cap plays out in the coming weeks.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Exploration Company Announces New Lithium Zones Findings
Shares Up on Registration News
Yet Another Biotech Making Major Moves
Most Popular
FREE Newsletter


Back to Top